Ketryx, a leading player in the intersection of healthcare and software, has successfully raised over $18 million in a recent funding round led by Lightspeed Venture Partners. The funding, which includes participation from existing investors such as MIT’s E14 Fund and Ubiquity Ventures, is set to propel Ketryx into a new phase of product development and commercial expansion. With Lightspeed partner Guru Chahal joining the board, Ketryx is poised to revolutionize medical software safety and reliability.
The healthcare industry is witnessing a paradigm shift with the increasing integration of software, especially Artificial Intelligence/Machine Learning (AI/ML), to enhance patient outcomes. However, this transformation comes with challenges related to quality assurance and regulatory compliance, particularly as software updates become more frequent and software complexity grows.
Ketryx, founded with a mission to enhance medical software safety and reliability, aims to reduce recalls and improve patient outcomes in a rapidly evolving healthcare landscape. As the demand for software in healthcare grows, Ketryx envisions expanding access to its platform and addressing the complexity of quality assurance in the industry.
Traditional manual approaches to software quality assurance are proving inadequate in the face of growing software complexity. Ketryx addresses this challenge by integrating automation and quality process enforcement into the software development lifecycle. This approach ensures that best practices are followed, and potential risks are proactively identified and mitigated before affecting performance.
Ketryx has assembled a team of experts with backgrounds in software development, regulation, and AI/ML. The team includes professionals from the FDA, Wolfram Research, and quality leaders from Amgen. By combining regulatory expertise with modern development practices, Ketryx is well-positioned to bring innovation to the healthcare software industry.
Ketryx has spent years designing products around FDA regulations and quality standards, resulting in a purpose-built connected lifecycle management platform. This platform automates and aligns many manual tasks and processes, providing automation for documentation, process enforcement, and traceability. Ketryx’s innovative solution transforms traditional development tools into an FDA-compliant single source of truth for the entire product lifecycle.
Customers using Ketryx can now automate traditionally manual tasks, allowing development teams to focus on modern DevTools and DevOps practices. Ketryx’s platform overlays and transforms development tools into an FDA-compliant system, ensuring automated documentation and compliance throughout the software development process.
Guru Chahal, Lightspeed partner and Ketryx board member, emphasizes the importance of enabling technology companies to be compliant with regulations without hindering innovation. Ketryx’s platform uniquely positions itself to help companies worldwide develop software faster while ensuring safety and compliance.
Ketryx is at the forefront of helping medical device manufacturers streamline their regulated development processes. The platform facilitates the delivery of safer software for various medical applications, including connected medical devices, drug delivery systems, surgical robotics, imaging diagnostics, and regulated medical apps like digital therapeutics.
Ketryx, with its latest funding round, is poised to bring about a transformation in medical software safety. By leveraging AI-driven quality assurance and automation, Ketryx aims to revolutionize the healthcare software industry, providing innovative solutions that prioritize both safety and compliance. As Ketryx continues its journey, it stands as a beacon for the future of healthcare technology.